Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuti (NQ: CYCC )

1.898 +0.048 (+2.61%)
Streaming Delayed Price Updated: 10:20 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclacel Pharmaceuti

< Previous 1 2 Next >
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma 
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Reverse Stock Split
From Cyclacel
Via GlobeNewswire
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
From Cyclacel
Via GlobeNewswire
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients 
From Cyclacel
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.